The Synaptic Vesicular Amine Transporter pipeline drugs market research report outlays comprehensive information on the Synaptic Vesicular Amine Transporter targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Synaptic Vesicular Amine Transporter pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
Smarter leaders trust GlobalData
The report also covers products from therapy areas such as Central Nervous System which include the indications Tardive Dyskinesia, and Huntington Disease. It also reviews key players involved in Synaptic Vesicular Amine Transporter targeted therapeutics development with respective active and dormant or discontinued products.
The Synaptic Vesicular Amine Transporter pipeline targets constitutes close to eight molecules. Out of which, approximately eight molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase II, IND/ CTA Filed, and Preclinical stages are 1, 3, 1, and 3 respectively.
Synaptic Vesicular Amine Transporter overview
Synaptic vesicular amine transporter (SLC18A2) acts as an ATP-dependent transporter of monoamines, such as dopamine, norepinephrine, serotonin, and histamine. SLC18A2 exchanges one cationic monoamine with two intravesicular protons across the membrane of secretory and synaptic vesicles. Also, uses the electrochemical proton gradient established by the V-type proton-pump ATPase to accumulate high concentrations of monoamines inside the vesicles prior to their release via exocytosis.
For a complete picture of Synaptic Vesicular Amine Transporter’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.
Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
